Last reviewed: May 18, 2026
Last updated: May 18, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
There is no single most effective GLP-1 for weight loss across all patients. Clinical trials show tirzepatide achieves up to 22% weight loss and semaglutide approximately 15%, but individual response varies significantly based on genetics, baseline metabolic status, and adherence.
Choosing the right GLP-1 requires understanding both clinical evidence and your personal metabolic context. PlexusDx supports this precision-wellness approach by combining comprehensive provider guidance with optional genetic insights into peptide pathways—helping you and your healthcare provider make informed decisions.
Clinical Evidence: How Semaglutide and Tirzepatide Compare
Semaglutide demonstrated approximately 15% average body weight reduction in STEP trials over 68 weeks at the 2.4 mg maintenance dose. Tirzepatide, a GIP/GLP-1 receptor agonist, showed 22% average weight loss in the SURMOUNT trial at the 15 mg dose over similar duration.
Neither drug works identically in every person. Response depends on baseline weight, insulin resistance, medication adherence, lifestyle factors, and individual receptor sensitivity. Your provider should assess which compound aligns with your specific metabolic profile and health goals.
Key Biomarkers and Metabolic Factors That Predict Response
Beyond medication type, several biomarkers help contextualize potential GLP-1 response. Fasting insulin, HbA1c, triglyceride levels, and baseline BMI all influence how effectively a given compound may work for you. A thorough metabolic assessment before starting therapy provides important clinical grounding.
| Biomarker |
Clinical Relevance to GLP-1 Response |
| Fasting Insulin |
Higher baseline insulin may predict stronger tirzepatide (dual GIP/GLP-1) benefit vs semaglutide alone |
| HbA1c |
Elevated HbA1c suggests insulin resistance; GLP-1 agents address this, but severity may guide dose planning |
| GLP1R Gene Variant (rs6923761) |
Genetic variation in GLP-1 receptor expression may contribute to individual medication responsiveness |
| FTO Gene Variant (rs9939609) |
FTO rs9939609 association with metabolic weight gain predisposition; genetic context supports personalized counseling |
| Triglyceride/HDL Ratio |
Dyslipidemia pattern indicates metabolic dysfunction severity; helps inform risk-benefit discussions |
Genetic Predispositions in Peptide Pathways: What You Should Know
Genetic variants in GLP-1 receptor (GLP1R), glucose-dependent insulinotropic polypeptide receptor (GIPR), melanocortin-4 receptor (MC4R), and fat mass obesity (FTO) genes are associated with appetite regulation and metabolic phenotype. These predispositions may help contextualize your response profile.
PlexusDx Precision Peptide Genetic Test analyzes key variants—including GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, and MC4R rs17782313—to reveal predispositions in peptide-signaling pathways. This information should be interpreted with your healthcare provider to support more informed, personalized conversations about medication selection and expected response patterns.
Safety, Tolerability, and Who Should Start GLP-1 Therapy
Both semaglutide and tirzepatide carry risks of nausea, vomiting, pancreatitis, and thyroid concerns. They require medical supervision, are contraindicated in personal or family history of medullary thyroid cancer, and demand careful dose titration. Only qualified healthcare providers should initiate and adjust therapy.
Effectiveness also depends on adherence and lifestyle. GLP-1 medications are most successful alongside sustainable dietary and exercise habits. Your provider should screen for contraindications, monitor for side effects, and adjust dosing based on your tolerability and metabolic response over time.
How PlexusDx Supports a More Personalized Approach
PlexusDx recognizes that 'most effective' is inherently personal. Our Precision Peptide Genetic Test may help provide context on your underlying genetic predispositions in appetite-regulation and metabolic pathways—insights that can support a more informed conversation with your healthcare provider about which GLP-1 compound and dosing strategy aligns with your genetic and biomarker profile.
The test reveals predispositions in four key peptide-signaling variants (GLP1R, GIPR, FTO, MC4R) that relate to how your body's appetite and metabolic systems respond to GLP-1 agonists. These predispositions do not predict exact medication response or guarantee outcomes, but they offer clinically relevant context that your provider can weigh alongside your metabolic labs, medical history, and personal goals.
When you combine genetic insights with biomarker assessment and provider guidance, you're positioned to make a more personalized treatment decision. PlexusDx compounded semaglutide and tirzepatide are available at multiple dose strengths through licensed 503A pharmacies—allowing your provider to select the option and starting dose most aligned with your clinical profile and response trajectory.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral starts at $279/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Related Reading
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Can I Change Semaglutide Injection Day? Clinical Guidance
Timeline for Weight Loss on Ozempic: Genetic & Biomarker Context